Cardio-diagnostic company adds new apoAI measurement and apoB/apoAI ratio to advanced lipid profile for heart disease risk stratification
BIRMINGHAM, Ala., March 17 /PRNewswire/ -- Atherotech, Inc., today announced it will be exhibiting its VAP(R) Cholesterol Test in booth #1263 at ACC.09, the American College of Cardiology (ACC) 58th Annual Scientific Session Exposition. The annual meeting takes place March 29-31, 2009, at the Orange County Convention Center in Orlando, Fla.
Used in more than 100 clinical trials, including the Heredity and Phenotype Intervention (HAPI) Heart Study recently published in Science, the VAP (Vertical Auto Profile) Test is the most accurate cholesterol test available today.
The VAP Test reports 20 separate components of blood cholesterol as opposed to four in a standard test and can identify a far great number of lipid abnormalities (the #1 risk factor for heart disease) than the standard cholesterol test. The test identifies markers for metabolic syndrome, a precursor for diabetes, and is the only single cholesterol test that routinely reports apoAI, apoB, and the apoB/apoAI ratio.
Atherotech recently announced the addition of apolipoprotein AI (apoAI), the main component of protective HDL cholesterol, to its reporting. Several large, prospective studies, including INTERHEART and the AMORIS trials, have clearly shown the apoB/apoAI ratio to be superior to all other cardiovascular disease risk marker ratios.
"ACC 2009 represents an excellent setting in which to convey the unique benefits of advanced cholesterol profiling to medical professionals from around the world," said Atherotech Chief Medical Officer James Ehrlich, M.D.
Atherotech representatives will be available to discuss the VAP Cholesterol Test in booth #1263, and blood draws will be provided to qualified attendees during exhibit hours March 29-
|SOURCE Atherotech, Inc.|
Copyright©2009 PR Newswire.
All rights reserved